Company: BIAF
Filing Date: 2025-05-23
Form Type: PRER14A
Source: 0001641172-25-012315
Chunk: 50

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-23
Form: PRER14A
Chunk 50
---
Proposal No. 7).

Vote Required

The affirmative vote of a majority of the votes cast by the holders of all shares of stock present or represented and voting on the Authorized Increase Proposal at the Annual Meeting is required to approve the Authorized Increase Proposal. This means that to be approved, the votes cast in favor of the Authorized Increase Proposal must exceed the votes cast against the Authorized Increase Proposal. Since abstentions are not considered votes cast, they will have no effect on this proposal. Broker non-votes are not expected for this proposal because we believe this matter is a routine matter. If there were to be any broker non-votes they would have no effect on the vote with respect to this proposal.

Approval by our stockholders of this Authorized Increase Proposal is not conditioned upon approval by our stockholders of the Reverse Stock Split Proposal (Proposal No. 3) or Anti-Dilution Adjustment Proposal (Proposal No. 6). However, the Approval of this Authorized Increase Proposal is a condition to any Anti-Dilution Adjustment (as defined below in Proposal No. 6 below) being effected.

<div align='center'>THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” APPROVAL OF THE

AUTHORIZED INCREASE PROPOSAL.</div>

| 26 |

<div align='center'>PROPOSAL NO. 6

APPROVAL OF THE ANTI-DILUTION ADJUSTMENT</div>

We are seeking stockholder approval of an Anti-Dilution Adjustment (as defined below) contained in the Common Stock purchase warrants (the “ May 2025 Warrants”) issued in connection with our best efforts public offering that closed on May 7, 2025, pursuant to which, upon our consummation of a Dilutive Issuance (defined below) and subject to approval of Proposal No. 5, the exercise price of the May 2025 Warrants would be reduced to a minimum price of $0.10 per share and, upon a reduction in the exercise price, the number of shares of Common Stock issuable upon exercise of the May 2025 Warrants would correspondingly be increased up to an aggregate maximum of 49,907,811 shares of our Common Stock (on a pre-reverse stock split basis which number shall be adjusted based on the reverse stock split ratio). A “ Dilutive Issuance” will occur if, in a subsequent offering of our securities, the price paid for Common Stock, the exercise price of any options or warrants or the conversion price